Page 23 - Lipids News Today

A study of firefighters who worked at the World Trade Center in New York in the aftermath of the 9/11 attacks suggests that a low-cal Mediterranean diet may protect against lung dysfunction.

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service.

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

New research being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Hamburg (2-6 Oct) finds that cigarette smoking increases the risk of developing type 2 diabetes in part by affecting a variety of metabolites-;small chemicals produced in the processes of metabolism-;that circulate in the bloodstream.

The AHA update now includes the use of venoarterial extracorporeal membrane oxygenation for patients whose condition is refractory to other treatments.

A study in Nature Communications delves into how the liver's circadian clock responds to meal timing, impacting fat metabolism and other bodily processes. The research underscores the intricate network that contributes to liver's diurnal rhythms, regulated by protein phosphorylation and nutrient availability.

Review sheds light on edible coatings as a sustainable alternative to traditional packaging and preservatives in the food industry, particularly for perishable items like fruits and vegetables.

New research finds that people with schizophrenia have a genetic propensity to smoking and a reduced genetic risk of obesity.

Liposomes have been used to enhance the effectiveness of medicines for decades – but it doesn’t necessarily mean they will work in food supplements too.

People 70 years of age and older taking LDL cholesterol-lowering therapy for primary prevention have the same reduction in major vascular events as their younger counterparts, new research confirms.